Article

Novel Oncolytic Virus VG161 in Hepatocellular Carcinoma Patients Refractory to Standard Systemic Therapies

2024-06-26

Abstract excerpt

<title>Abstract</title> <p>For hepatocellular carcinoma (HCC) patients, treatment options are limited after failing second-line therapy. This phase I, multicenter trial evaluates the safety and antitumor efficacy of VG161 in patients with advanced liver cancer. The study included dose escalation using a ‘3 + 3’ design across five dose levels, followed by a dose expansion phase using Simon’s two-stage design. Fort...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dbc692a6-5523-5812-85df-aab11e00081b
DOI: 10.21203/rs.3.rs-4608261/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Novel Oncolytic Virus VG161 in Hepatocellular Carcinoma Patients Refractory to Standard Systemic TherapiesDOI 10.21203/rs.3.rs-4608261/v1Read

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read

OvirusTdb: A database of oncolytic viruses for the advancement of therapeutics in cancerSemantic proximity Read

Safety and efficacy of immune checkpoint inhibitors in nasopharyngeal carcinoma patients with chronic hepatitis B virus infectionSemantic proximity Read

First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor ActivitySemantic proximity Read

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.Semantic proximity Read

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapySemantic proximity Read

Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1.Semantic proximity Read

Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver CancersSemantic proximity Read

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.Semantic proximity Read

A modified oncolytic measles virus exhibits strong immunotherapeutic potential through RIG-I activation by defective viral genomesSemantic proximity Read

Viruses of Avian Origin for Cancer VirotherapySemantic proximity Read

A Replication‐Defective Myxoma Virus Inducing Pro‐Inflammatory Responses as Monotherapy and an Adjuvant to Chemo‐ and DC Immuno‐Therapy for Ovarian CancerSemantic proximity Read